Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06672055 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
A Phase 2 study of COVID-19 and Sars-CoV2, sponsored by Vaxart.
- Active
- Registry status
- Phase 2
- Development phase
- 10,400
- Enrollment target
- 20
- Study locations
NCT06672055 is a Phase 2 study of COVID-19 and Sars-CoV2 that is active but no longer recruiting, run by Vaxart. The registered enrollment target is 10,400 participants, below the 55,163-participant average among 203 other COVID-19 trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT06672055, a Phase 2 study of COVID-19 and Sars-CoV2, is active but no longer recruiting, sponsored by Vaxart.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 10,400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19). In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain) vaccine.
Interventions
- BIOLOGICAL COMIRNATY®
- BIOLOGICAL VXA-CoV2-3.1
- BIOLOGICAL VXA-CoV2-3.3
Study Locations (20)
California
- Elligo Health Research (BTC/ClinEdge) - Core Healthcare Group - Cerritos
- Velocity Clinical Research - Chula Vista (eStudySite - Chula Vista) - Chula Vista
- Avacare - Benchmark Research - SOCAL-Colton - Colton
- Altasciences Los Angeles (Formerly WCCT Global) - Cypress
- Ark Clinical Research - Fountain Valley, CA - Fountain Valley
- Velocity Clinical Research - San Diego (eStudySite - La Mesa) - La Mesa
- Ark Clinical Research - Long Beach, CA - Long Beach
- Velocity Clinical Research (National Research Institute) - Panorama City - Los Angeles
- Northern California Research - Sacramento
- Avacare - Benchmark Research - Sacramento - Sacramento
- Velocity Clinical Research - Gardena - Santa Ana
Arizona
- Avacare - Lenzmeier Family Medicine - Glendale
- Desert Clinical Research - Mesa
- Velocity Clinical Research - MedPharmics - Phoenix - Phoenix
- Foothills Research Center - Phoenix
- Avacare (CCT) - Fiel Family & Sports Medicine - Tempe
Alabama
- Pinnacle Research Group - Anniston
- Core Clinical Trials - Central Alabama Research LLC - Birmingham
- Coastal Clinical Research - Mobile
Arkansas
- Baptist Health Center for Clinical Research - Little Rock - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,400 participants |
| Start Date | 2024-10-08 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06672055
The ClinicalTrials.gov registry entry for NCT06672055 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 10,400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,163-participant average among 203 other COVID-19 trials with a reported enrollment target (81% lower). The listed sponsor is Vaxart, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 3 interventions - of which COMIRNATY® is the first listed.
NCT06672055 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT06672055 about?
NCT06672055 is a clinical study titled "A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection". The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-1...
What is the current status of trial NCT06672055?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 10,400 participants. The study started on 2024-10-08. Estimated completion is 2026-11.
What conditions does trial NCT06672055 study?
This clinical trial studies the following conditions: COVID-19, Sars-CoV2.
What interventions are being tested in trial NCT06672055?
The interventions under investigation include: COMIRNATY® (BIOLOGICAL), VXA-CoV2-3.1 (BIOLOGICAL), VXA-CoV2-3.3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06672055?
This trial is sponsored by Vaxart, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06672055 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.